Tranexamic acid is permitted for use in cosmetics in both the United States and the European Union, but the regulatory framing differs meaningfully between the two regions.
In the United States, the FDA does not regulate cosmetic ingredients through a pre-market approval system (with the exception of color additives). Tranexamic acid is not on the FDA's prohibited or restricted ingredient list, so it may be used in cosmetic formulations without prior approval. However, the claims you make about the product determine whether it is regulated as a cosmetic or an OTC drug. Claims that reference physiological activity — such as "inhibits melanin production" or "skin-lightening" — may trigger the FDA's OTC drug monograph framework. Most US brands position TXA products using cosmetic-compliant language such as "visibly brightens uneven skin tone" or "reduces the appearance of dark spots" to stay firmly in cosmetic territory. There is currently no formal OTC drug monograph for TXA-based skin-lightening products in the US, which means products making drug-level lightening claims would be considered unapproved new drugs.
In the European Union, cosmetic ingredients are regulated under Regulation (EC) No. 1223/2009. Tranexamic acid is not listed in Annex II (prohibited substances) or Annex III (restricted substances) as of the time of writing, meaning it may be used as a cosmetic active without restriction. However, an EU-responsible person must commission a Cosmetic Product Safety Report (CPSR) from a qualified safety assessor before placing any TXA-containing product on the EU market. The CPSR must confirm that the concentration of TXA used is safe for the intended route of exposure (topical, leave-on, body butter).
For the UK post-Brexit, the UK Cosmetics Regulation (retained EU law, SI 2019/696) applies substantially the same rules as the EU framework. A UK responsible person and a UK CPSR are required for products sold in Great Britain.
In South Korea, one of the largest markets for brightening actives, tranexamic acid is classified as a "functional cosmetic" ingredient when used for skin brightening, and the product must be registered with the Ministry of Food and Drug Safety (MFDS) before sale. This is a meaningful additional step compared to US or EU requirements.
A common first-timer mistake is assuming that because TXA is not on a banned list, no regulatory homework is needed. The claim review, INCI labeling accuracy, and stability data requirements still apply in every market. Your manufacturer should provide the INCI name (Tranexamic Acid) in the correct descending order on the label, and your compliance review should happen before, not after, production.
Ingredients in this answer: Tranexamic Acid
Read the full guide on Private Label Tranexamic Acid Body Butter Manufacturer →